Share on StockTwits

Geron (NASDAQ:GERN) is scheduled to be posting its Q214 quarterly earnings results on Monday, August 11th. Analysts expect Geron to post earnings of ($0.06) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Geron (NASDAQ:GERN) opened at 2.41 on Friday. Geron has a 52 week low of $1.2004 and a 52 week high of $7.3629. The stock’s 50-day moving average is $2.69 and its 200-day moving average is $2.81. The company’s market cap is $378.2 million.

On a related note, analysts at MLV & Co
upgraded shares of Geron from a “hold” rating to a “buy” rating in a research note on Thursday, June 12th. They now have a $4.25 price target on the stock, up previously from $2.00. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $4.25.

Geron Corporation (NASDAQ:GERN) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Receive News & Ratings for Geron Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Co and related companies with Analyst Ratings Network's FREE daily email newsletter.